MIS in Cardiovascular: The Last Best Hope
Now it is appropriate to ask whether, for product companies in particular, cardiovascular represents the final and full realization of MIS' promise-or another bumpy ride with disappointment the only certain endpoint. Sidebar: Angioplasty and the MISThreat: The advent of MIS resurrects the historic rivalry between interventional cardiology and cardiac surgeons.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.